ISSN: 1776-2596

Journal Home

Journal Guideline

Targeted Oncology Q1 Unclaimed

Springer Paris France

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Targeted Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 59. It has a price of 3190 €. It has an SJR impact factor of 1,421 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,421.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1) Pharmacology (medical) (Q1) Cancer Research (Q2)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,421

SJR Impact factor

59

H Index

80

Total Docs (Last Year)

206

Total Docs (3 years)

3070

Total Refs

815

Total Cites (3 years)

200

Citable Docs (3 years)

3.84

Cites/Doc (2 years)

38.38

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy

New therapies in squamous cell carcinoma of the head and neck: is the future in combined therapies?

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases

Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report

Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer

The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX

Erratum to: Nuclear imaging of molecular processes in cancer

Combining targeted therapies

Streptozocin-based chemotherapy is not history in neuroendocrine tumours

The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials

Sunitinib in pancreatic neuroendocrine tumors

The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells

SHOW MORE ARTICLES

Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment

ESMO 2014: new trends in precision medicine

Molecular imaging in clinical trials

Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma

Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma

Treatment of advanced thyroid cancer: role of molecularly targeted therapies

The toxicities of modern targeted therapies - learning from the price of progress

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

New treatment options with cytotoxic agents in neuroendocrine tumours

Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab